top of page

Startup Vesica Health to Revive MDxHealth Bladder Cancer Assay Boosted by New Clinical Impact Data

Molika Ashford

Oct 20, 2023

According to Vesica, the AssureDx test conferred a statistically significant improvement in the identification of patients at increased risk for bladder cancer over AUA measures alone. Notably, in patients with microhematuria, the assay showed an area under the receiver operating curve of 0.97, with a positive test result resulting in a fivefold increase in the risk of harboring bladder cancer compared to the current risk assessment metrics alone.

bottom of page